The Swiss coronary stent company Qvanteq AG enrolled first patient in the QUEST I clinical study
Qvanteq AG today announced that it has enrolled the first patient in the First in Man (FiM) clinical study QUEST I, this is following earlier regulatory approval from the Dutch and Swiss authorities. The aim of the QUEST I study is to assess feasibility and safety of the Qstent, a bioactive, coating-free coronary stent. The Qstent has shown excellent in-growth and low thrombogenicity in pre-clinical studies. Continue reading
Qvanteq is a Top 100 Swiss Startup
Qvanteq was amongst the “Top 100 Swiss Startups” for the 4th time in a row.
CTI Swiss medtech best poster award 2014
Qvanteq won the CTI best poster award. Read more
Effect of oxide layer modification of CoCr stent alloys on blood activation and endothelial behavior
Vincent Milleret1,†, Algirdas Ziogas1,†, Stefano Buzzi2, Roman Heuberger3, Arik Zucker2 and Martin Ehrbar1,*